FDA Approves TECNIS PureSee IOL for Cataract Surgery
First FDA-approved extended depth of focus (EDOF) IOL maintaining contrast sensitivity comparable to an aspheric monofocal IOL
Clinical Scorecard: FDA Approves TECNIS PureSee IOL for Cataract Surgery
At a Glance
Category Detail
Condition Cataracts and presbyopia Key Mechanisms Extended depth of focus (EDOF) intraocular lens (IOL) that addresses cataract-related vision loss and presbyopia effects. Target Population Patients aged 50 and over with moderate-to-severe distance vision impairment or blindness. Care Setting Cataract surgery
Key Highlights
First FDA-approved EDOF IOL with no warning on loss of contrast sensitivity. Maintains contrast sensitivity comparable to aspheric monofocal IOLs. 97% of patients report no very bothersome visual disturbances post-surgery. Provides excellent distance and intermediate vision, with some near vision. Reduces reliance on glasses following surgery. Guideline-Based Recommendations
Diagnosis
Assess cataract severity and impact on vision. Management
Consider TECNIS PureSee IOL for patients undergoing cataract surgery. Monitoring & Follow-up
Evaluate visual outcomes and patient satisfaction post-surgery. Risks
Monitor for potential visual disturbances, although low incidence reported. Patient & Prescribing Data
Patients aged 50 and over with cataracts and presbyopia.
TECNIS PureSee IOL offers a solution for both cataract correction and presbyopia management.
Clinical Best Practices
Ensure thorough pre-operative assessment of visual needs. Discuss potential outcomes and benefits of TECNIS PureSee IOL with patients. Follow up with patients to monitor visual clarity and satisfaction. Related Resources & Content
